FDA’s June approvals included Tregzi (Orca-T), described as the first approved allogeneic regulatory T cell-based therapy for hematological malignancies in matched-donor hematopoietic stem cell transplantation. The product is positioned to rebuild the patient’s immune and blood systems while using purified Tregs to limit graft-versus-host disease, with use alongside a myeloablative regimen.